TRIDENT flop then pancreatic CE Mark and raised guidance lift Novocure
TRIDENT trial fails primary endpoint Novocure's Phase 3 TRIDENT trial missed its main goal: starting Tumor Treating Fields earlier did not clearly extend overall survival in newly diagnosed glioblastoma. The stock fell about 20% as hopes for a broader label in this cancer faded.
This is the period's biggest negative event and explains the initial sharp drop.
Securities fraud investigation after TRIDENT Law firm Pomerantz is investigating Novocure for possible securities fraud tied to the TRIDENT miss. Such probes can bring legal costs, distract management, and keep some investors cautious, adding pressure on the shares.
It is a new legal overhang directly linked to the trial failure.
Optune Pax wins CE Mark for pancreatic cancer Novocure's Optune Pax received European CE Mark approval for locally advanced pancreatic cancer, backed by the PANOVA-3 trial showing longer survival and delayed pain. Launch starts in Germany, opening a new market and revenue stream.
This is a fresh regulatory win that expands the addressable market beyond brain cancer.
Q2 revenue beat and raised 2026 guidance Second-quarter revenue rose 16% to $183.6 million, and Novocure raised full-year 2026 revenue guidance to $710–$725 million while projecting positive adjusted EBITDA. The stock hit a 52-week high as investors grew more confident in the core business.
This is the main positive catalyst that reversed the earlier decline and drove the new high.